PVRi

Drug Discovery & Development Symposium 2025

Inclusive & sustainable drug development for Pulmonary Arterial Hypertension (PAH)

16 - 17 June 2025

Mercure Amsterdam City Hotel
Joan Muyskenweg 10, 1096 CJ,
Amsterdam, Netherlands

Scientific programme: 16 June 2025

Inclusive & sustainable drug development for PAH

08:00-08:25	Welcome tea & coffee
08:25-08:30	Welcome Anna Hemnes, PVRI President 2024-2026

SESSION 1: New standards of care

Moderators: Anna Hemnes, Harm Jan Bogaard

08:30-09:00	Global perspective on regulatory approval of Sotatercept Representatives from FDA: Mitchel Psotka (virtual), EMA (TBC)
09:00-09:20	How Sotatercept will change the treatment algorithm Luke Howard
09:20-09:40	Implications of a new background therapy for drug development Marion Delcroix
09:40-10:00	Panel & delegate discussion All session speakers & moderators

SESSION 2: Disease modification

Moderators: Zhi-Cheng Jing, Martin Wilkins

10:00-10:20	How to define or prove disease modification Mark Toshner
10:20-10:40	The role of imaging in establishing disease modifying effects of a trial drug Sudarshan Rajagopal
10:40-10:50	Panel & delegate discussion All session speakers & moderators
10:50-11:10	Refreshment break

SESSION 3: Diversity & inclusion

Moderators: Gergely Meszaros, Esther Nossent

11:10-11:30	Addressing sex differences in treatment decisions & drug development Deimante Hoppenot
11:30-11:50	How to include underrepresented patients into cardiovascular clinical trials Cati Brown-Johnson
11:50-12:00	Panel & delegate discussion All session speakers & moderators

SESSION 4: Global aspects of drug development & availability

Moderators: Anton Vonk-Noordegraaf, Deimante Hoppenot

12:00-12:15	Using the GoDeep Registry to prioritise & facilitate global drug trials Werner Seeger
12:15-12:40	Pro/con debate: It is Big Pharma's responsibility to prioritise drug availability over drug discovery Pro: Anna Hemnes / Con: Ardeschir Ghofrani
12:40-13:00	Panel & delegate discussion All session speakers & moderators
13:00-14:00	Lunch break

SESSION 5: Innovations in trial design

Moderators: Athénaïs Boucly, Frances Varian

14:00-14:20	How to use risk scores (enrichment, endpoints) Athénaïs Boucly
14:20-14:40	How to use imaging endpoints reflecting the pulmonary circulation & RV David Kiely
14:40-15:10	n=1 trials & randomised withdrawal studies Martin Wilkins
15:10-15:30	Panel & delegate discussion All session speakers & moderators
15:30-15:50	Refreshment break
15:50-16:10	Novel statistical approaches: Bayesian statistics, use of win ratio Alex Rothman
16:10-16:30	Practical & ethical aspects around OLE studies Harm Jan Bogaard
16:30-16:50	Climate impact of drug development Frances Varian
16:50-17:10	Panel & delegate discussion All session speakers & moderators
17:10-19:00	Networking drinks reception